Immunome (NASDAQ:IMNM) Hits New 1-Year Low - Should You Sell?

Immunome, Inc. (NASDAQ:IMNM - Get Free Report)'s stock price hit a new 52-week low during trading on Monday . The stock traded as low as $8.51 and last traded at $8.88, with a volume of 395083 shares traded. The stock had previously closed at $9.34.

Analysts Set New Price Targets

Several brokerages have recently commented on IMNM. Wedbush reissued an "outperform" rating and set a $33.00 price target on shares of Immunome in a research note on Monday. Piper Sandler decreased their price target on Immunome from $23.00 to $21.00 and set an "overweight" rating on the stock in a research note on Thursday, November 14th. Finally, Lifesci Capital began coverage on Immunome in a research note on Tuesday. They set an "outperform" rating and a $20.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Immunome currently has an average rating of "Buy" and an average target price of $27.17.

Immunome Trading Down 1.2 %

The business has a 50 day moving average of $10.06 and a 200-day moving average of $11.87. The stock has a market cap of $704.03 million, a PE ratio of -1.09 and a beta of 1.93.

Insider Activity at Immunome

In other Immunome news, CEO Clay B. Siegall purchased 150,000 shares of the firm's stock in a transaction on Friday, January 31st. The shares were purchased at an average cost of $7.75 per share, with a total value of $1,162,500.00. Following the purchase, the chief executive officer now owns 669,636 shares in the company, valued at approximately $5,189,679. This represents a 28.87 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 8.60% of the stock is owned by corporate insiders.

Remove Ads

Institutional Investors Weigh In On Immunome

Institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets purchased a new stake in Immunome in the fourth quarter valued at approximately $70,000. KLP Kapitalforvaltning AS purchased a new stake in Immunome in the fourth quarter valued at approximately $75,000. AlphaQuest LLC grew its holdings in Immunome by 786,700.0% in the fourth quarter. AlphaQuest LLC now owns 7,868 shares of the company's stock valued at $84,000 after purchasing an additional 7,867 shares during the period. Tower Research Capital LLC TRC grew its holdings in Immunome by 482.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock valued at $91,000 after purchasing an additional 7,129 shares during the period. Finally, Aquatic Capital Management LLC purchased a new stake in Immunome in the fourth quarter valued at approximately $95,000. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.